Biology Reference
In-Depth Information
110. PhamW, Choi Y, Weissleder R, Tung CH. Developing a peptide-based near-infrared
molecular probe for protease sensing.
Bioconjug Chem
2004;
15
:1403-7.
111. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis, and char-
acterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Chem
Biol
2004;
11
:99-106.
112. Tung CH, Gerszten RE, Jaffer FA, Weissleder R. A novel near-infrared fluorescence
sensor for detection of thrombin activation in blood.
Chembiochem
2002;
3
:207-11.
113. Penna FJ, Freilich DA, Alvarenga C, Nguyen HT. Improving lymph node yield in ret-
roperitoneal
lymph node dissection using fluorescent molecular imaging: a novel
method of
localizing lymph nodes in Guinea pig model.
Urology
2011;
78
(232):
e15-e18.
114. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by
means of proteolytic activation of cell-penetrating peptides.
Proc Natl Acad Sci USA
2004;
101
:17867-72.
115. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al. In vivo char-
acterization of activatable cell penetrating peptides for targeting protease activity in can-
cer.
Integr Biol (Camb)
2009;
1
:382-93.
116. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, Ryan C, et al. Activity-based
probes that target diverse cysteine protease families.
Nat Chem Biol
2005;
:33-8.
117. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, et al. Dynamic im-
aging of protease activity with fluorescently quenched activity-based probes.
Nat Chem
Biol
2005;
1
:203-9.
118. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical
imaging of cysteine protease activity using fluorescently quenched activity-based pro-
bes.
Nat Chem Biol
2007;
3
:668-77.
119. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for fluores-
cent probe design in medical diagnostic imaging.
Chem Rev
2010;
110
:2620-40.
120. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease.
Circu-
lation
2007;
116
:1052-61.
121. Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, Grone HJ. Immunohistochem-
ical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic
lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.
Eur J
Biochem
2000;
267
:4495-503.
122. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al.
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.
Circulation
2003;
108
:1440-5.
123. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al.
Prognostic value of myeloperoxidase in patients with chest pain.
N Engl J Med
2003;
349
:1595-604.
124. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, et al.
Myeloperoxidase predicts progression of carotid stenosis in states of low high-density
lipoprotein cholesterol.
J Am Coll Cardiol
2006;
47
:2212-8.
125. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M,
Molina CA, et al. Increased brain expression of matrix metalloproteinase-9 after ische-
mic and hemorrhagic human stroke.
Stroke
2006;
1
:1399-406.
126. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix
metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications
after thrombolysis in human stroke.
Circulation
2003;
107
:598-603.
127. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I,
et al. A matrix metalloproteinase protein array reveals a strong relation between
MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
Stroke
2005;
36
:1415-20.
37
Search WWH ::
Custom Search